期刊
ENDOCRINE PATHOLOGY
卷 26, 期 2, 页码 95-103出版社
HUMANA PRESS INC
DOI: 10.1007/s12022-015-9362-y
关键词
Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells
资金
- European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]
- VEGA from Ministry of Education, Science, Research and Sport of the Slovak Republic [1/0592/13, 1/0754/15]
Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据